data_1tor_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1tor _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 38.1 t-105 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -49.88 159.42 0.75 Allowed Pre-proline 0 N--CA 1.481 1.076 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -63.33 -11.94 28.02 Favored 'Trans proline' 0 CA--C 1.543 0.946 0 C-N-CA 122.575 2.184 . . . . 0.0 117.085 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 36.67 1.65 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 118.642 0.656 . . . . 0.0 111.377 168.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -154.62 -92.42 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -66.66 -48.94 67.79 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.87 -12.31 53.56 Favored Glycine 0 CA--C 1.541 1.715 0 N-CA-C 116.414 1.326 . . . . 0.0 116.414 177.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.46 -65.04 1.71 Allowed Glycine 0 N--CA 1.47 0.931 0 CA-C-N 118.611 1.206 . . . . 0.0 112.429 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.3 tp -92.79 -55.03 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.704 -0.748 . . . . 0.0 112.154 -174.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? . . . . . 0 C--O 1.27 2.133 0 CA-C-N 119.493 1.042 . . . . 0.0 108.72 178.756 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 . . . . . 0 N--CA 1.475 0.79 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -155.48 163.42 24.7 Favored Pre-proline 0 CA--C 1.56 1.335 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -55.65 -36.92 95.65 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.115 1.876 . . . . 0.0 116.598 -177.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.7 44.63 1.08 Allowed 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 172.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -154.77 -73.32 0.12 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 175.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 25.5 t80 -78.62 -44.25 24.37 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 121.987 -0.446 . . . . 0.0 111.809 174.371 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.95 -36.95 91.83 Favored Glycine 0 CA--C 1.545 1.967 0 N-CA-C 115.511 0.964 . . . . 0.0 115.511 178.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -75.46 -78.26 0.66 Allowed Glycine 0 CA--C 1.536 1.357 0 CA-C-N 117.921 0.861 . . . . 0.0 112.729 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.7 tp -78.83 -39.06 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -171.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt . . . . . 0 C--O 1.251 1.136 0 CA-C-N 119.162 0.892 . . . . 0.0 110.165 -174.387 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 25.5 t-105 . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . 0.411 ' HB2' ' HD2' ' A' ' 3' ' ' PRO . 10.4 p30 -66.13 166.8 14.5 Favored Pre-proline 0 CA--C 1.55 0.958 0 O-C-N 121.803 -0.561 . . . . 0.0 112.077 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 2' ' ' ASN . 28.7 Cg_endo -73.5 15.89 0.51 Allowed 'Trans proline' 0 CA--C 1.543 0.938 0 N-CA-C 116.386 1.648 . . . . 0.0 116.386 -171.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -33.95 61.99 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 121.268 -0.895 . . . . 0.0 112.21 164.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -127.14 -62.86 1.08 Allowed 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.879 -0.513 . . . . 0.0 112.377 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -88.46 -48.46 7.59 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.272 -0.893 . . . . 0.0 112.314 -172.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.48 -48.28 82.09 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 115.469 0.948 . . . . 0.0 115.469 -168.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.34 -40.57 96.17 Favored Glycine 0 CA--C 1.536 1.361 0 C-N-CA 120.462 -0.875 . . . . 0.0 114.911 -175.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.401 HG22 ' H ' ' A' ' 10' ' ' LYS . 8.0 tp -93.06 -65.91 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 117.704 0.752 . . . . 0.0 110.804 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . 0.401 ' H ' HG22 ' A' ' 9' ' ' ILE . 4.4 mptp? . . . . . 0 C--O 1.251 1.161 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 176.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 63.6 t-105 . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.695 0.283 . . . . 0.0 111.309 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -61.1 156.36 49.56 Favored Pre-proline 0 N--CA 1.477 0.905 0 O-C-N 121.876 -0.515 . . . . 0.0 111.267 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.54 27.76 0.49 Allowed 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 121.803 1.669 . . . . 0.0 114.35 -173.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -109.56 2.93 20.69 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.606 -0.684 . . . . 0.0 112.042 168.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -150.55 -83.04 0.1 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -69.47 -45.85 68.05 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.416 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.64 -11.0 64.86 Favored Glycine 0 CA--C 1.542 1.755 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.061 178.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.98 -62.79 3.22 Favored Glycine 0 N--CA 1.469 0.884 0 C-N-CA 120.022 -1.085 . . . . 0.0 111.404 177.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.6 tp -85.92 -45.58 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.387 -174.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.6 mptp? . . . . . 0 C--O 1.25 1.105 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 172.219 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 13.3 t-105 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -156.53 172.86 5.55 Favored Pre-proline 0 CA--C 1.565 1.556 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -64.13 -28.33 65.11 Favored 'Trans proline' 0 CA--C 1.554 1.518 0 N-CA-C 115.757 1.407 . . . . 0.0 115.757 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.86 19.15 4.24 Favored 'General case' 0 CA--C 1.562 1.407 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 171.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -140.63 -78.59 0.29 Allowed 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -78.03 -44.67 25.82 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.682 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.04 -25.65 68.27 Favored Glycine 0 CA--C 1.552 2.357 0 C-N-CA 120.472 -0.87 . . . . 0.0 114.952 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.32 2.49 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.484 174.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.0 tp -88.13 -46.04 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 120.296 -0.562 . . . . 0.0 112.385 -169.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 118.462 -0.78 . . . . 0.0 110.065 -171.716 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 38.1 t-105 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -49.88 159.42 0.75 Allowed Pre-proline 0 N--CA 1.481 1.076 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -63.33 -11.94 28.02 Favored 'Trans proline' 0 CA--C 1.543 0.946 0 C-N-CA 122.575 2.184 . . . . 0.0 117.085 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 36.67 1.65 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 118.642 0.656 . . . . 0.0 111.377 168.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -154.62 -92.42 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -66.66 -48.94 67.79 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.87 -12.31 53.56 Favored Glycine 0 CA--C 1.541 1.715 0 N-CA-C 116.414 1.326 . . . . 0.0 116.414 177.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.46 -65.04 1.71 Allowed Glycine 0 N--CA 1.47 0.931 0 CA-C-N 118.611 1.206 . . . . 0.0 112.429 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.3 tp -92.79 -55.03 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.704 -0.748 . . . . 0.0 112.154 -174.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? . . . . . 0 C--O 1.27 2.133 0 CA-C-N 119.493 1.042 . . . . 0.0 108.72 178.756 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 . . . . . 0 N--CA 1.475 0.79 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -155.48 163.42 24.7 Favored Pre-proline 0 CA--C 1.56 1.335 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -55.65 -36.92 95.65 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.115 1.876 . . . . 0.0 116.598 -177.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.7 44.63 1.08 Allowed 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 172.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -154.77 -73.32 0.12 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 175.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 25.5 t80 -78.62 -44.25 24.37 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 121.987 -0.446 . . . . 0.0 111.809 174.371 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.95 -36.95 91.83 Favored Glycine 0 CA--C 1.545 1.967 0 N-CA-C 115.511 0.964 . . . . 0.0 115.511 178.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -75.46 -78.26 0.66 Allowed Glycine 0 CA--C 1.536 1.357 0 CA-C-N 117.921 0.861 . . . . 0.0 112.729 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.7 tp -78.83 -39.06 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -171.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt . . . . . 0 C--O 1.251 1.136 0 CA-C-N 119.162 0.892 . . . . 0.0 110.165 -174.387 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 25.5 t-105 . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . 0.411 ' HB2' ' HD2' ' A' ' 3' ' ' PRO . 10.4 p30 -66.13 166.8 14.5 Favored Pre-proline 0 CA--C 1.55 0.958 0 O-C-N 121.803 -0.561 . . . . 0.0 112.077 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 2' ' ' ASN . 28.7 Cg_endo -73.5 15.89 0.51 Allowed 'Trans proline' 0 CA--C 1.543 0.938 0 N-CA-C 116.386 1.648 . . . . 0.0 116.386 -171.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -33.95 61.99 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 121.268 -0.895 . . . . 0.0 112.21 164.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -127.14 -62.86 1.08 Allowed 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.879 -0.513 . . . . 0.0 112.377 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -88.46 -48.46 7.59 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.272 -0.893 . . . . 0.0 112.314 -172.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.48 -48.28 82.09 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 115.469 0.948 . . . . 0.0 115.469 -168.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.34 -40.57 96.17 Favored Glycine 0 CA--C 1.536 1.361 0 C-N-CA 120.462 -0.875 . . . . 0.0 114.911 -175.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.401 HG22 ' H ' ' A' ' 10' ' ' LYS . 8.0 tp -93.06 -65.91 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 117.704 0.752 . . . . 0.0 110.804 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . 0.401 ' H ' HG22 ' A' ' 9' ' ' ILE . 4.4 mptp? . . . . . 0 C--O 1.251 1.161 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 176.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 63.6 t-105 . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.695 0.283 . . . . 0.0 111.309 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -61.1 156.36 49.56 Favored Pre-proline 0 N--CA 1.477 0.905 0 O-C-N 121.876 -0.515 . . . . 0.0 111.267 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.54 27.76 0.49 Allowed 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 121.803 1.669 . . . . 0.0 114.35 -173.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -109.56 2.93 20.69 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.606 -0.684 . . . . 0.0 112.042 168.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -150.55 -83.04 0.1 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -69.47 -45.85 68.05 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.416 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.64 -11.0 64.86 Favored Glycine 0 CA--C 1.542 1.755 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.061 178.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.98 -62.79 3.22 Favored Glycine 0 N--CA 1.469 0.884 0 C-N-CA 120.022 -1.085 . . . . 0.0 111.404 177.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.6 tp -85.92 -45.58 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.387 -174.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.6 mptp? . . . . . 0 C--O 1.25 1.105 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 172.219 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 13.3 t-105 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -156.53 172.86 5.55 Favored Pre-proline 0 CA--C 1.565 1.556 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -64.13 -28.33 65.11 Favored 'Trans proline' 0 CA--C 1.554 1.518 0 N-CA-C 115.757 1.407 . . . . 0.0 115.757 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.86 19.15 4.24 Favored 'General case' 0 CA--C 1.562 1.407 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 171.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -140.63 -78.59 0.29 Allowed 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -78.03 -44.67 25.82 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.682 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.04 -25.65 68.27 Favored Glycine 0 CA--C 1.552 2.357 0 C-N-CA 120.472 -0.87 . . . . 0.0 114.952 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.32 2.49 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.484 174.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.0 tp -88.13 -46.04 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 120.296 -0.562 . . . . 0.0 112.385 -169.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 118.462 -0.78 . . . . 0.0 110.065 -171.716 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 38.1 t-105 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -49.88 159.42 0.75 Allowed Pre-proline 0 N--CA 1.481 1.076 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -63.33 -11.94 28.02 Favored 'Trans proline' 0 CA--C 1.543 0.946 0 C-N-CA 122.575 2.184 . . . . 0.0 117.085 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 36.67 1.65 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 118.642 0.656 . . . . 0.0 111.377 168.629 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -154.62 -92.42 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -66.66 -48.94 67.79 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.87 -12.31 53.56 Favored Glycine 0 CA--C 1.541 1.715 0 N-CA-C 116.414 1.326 . . . . 0.0 116.414 177.414 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.46 -65.04 1.71 Allowed Glycine 0 N--CA 1.47 0.931 0 CA-C-N 118.611 1.206 . . . . 0.0 112.429 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.3 tp -92.79 -55.03 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.704 -0.748 . . . . 0.0 112.154 -174.003 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? . . . . . 0 C--O 1.27 2.133 0 CA-C-N 119.493 1.042 . . . . 0.0 108.72 178.756 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 . . . . . 0 N--CA 1.475 0.79 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -155.48 163.42 24.7 Favored Pre-proline 0 CA--C 1.56 1.335 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -55.65 -36.92 95.65 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.115 1.876 . . . . 0.0 116.598 -177.171 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.7 44.63 1.08 Allowed 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 172.59 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -154.77 -73.32 0.12 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 175.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 25.5 t80 -78.62 -44.25 24.37 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 121.987 -0.446 . . . . 0.0 111.809 174.371 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.95 -36.95 91.83 Favored Glycine 0 CA--C 1.545 1.967 0 N-CA-C 115.511 0.964 . . . . 0.0 115.511 178.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -75.46 -78.26 0.66 Allowed Glycine 0 CA--C 1.536 1.357 0 CA-C-N 117.921 0.861 . . . . 0.0 112.729 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.7 tp -78.83 -39.06 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -171.139 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt . . . . . 0 C--O 1.251 1.136 0 CA-C-N 119.162 0.892 . . . . 0.0 110.165 -174.387 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 25.5 t-105 . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ASN . . . . . 0.436 ' HB2' ' HD2' ' A' ' 3' ' ' PRO . 10.4 p30 -66.13 166.8 14.5 Favored Pre-proline 0 CA--C 1.55 0.958 0 O-C-N 121.803 -0.561 . . . . 0.0 112.077 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 2' ' ' ASN . 28.7 Cg_endo -73.5 15.89 0.51 Allowed 'Trans proline' 0 CA--C 1.543 0.938 0 N-CA-C 116.386 1.648 . . . . 0.0 116.386 -171.502 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -33.95 61.99 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 121.268 -0.895 . . . . 0.0 112.21 164.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -127.14 -62.86 1.08 Allowed 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.879 -0.513 . . . . 0.0 112.377 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -88.46 -48.46 7.59 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.272 -0.893 . . . . 0.0 112.314 -172.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.48 -48.28 82.09 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 115.469 0.948 . . . . 0.0 115.469 -168.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.34 -40.57 96.17 Favored Glycine 0 CA--C 1.536 1.361 0 C-N-CA 120.462 -0.875 . . . . 0.0 114.911 -175.518 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.435 HG23 ' H ' ' A' ' 10' ' ' LYS . 8.0 tp -93.06 -65.91 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 117.704 0.752 . . . . 0.0 110.804 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LYS . . . . . 0.435 ' H ' HG23 ' A' ' 9' ' ' ILE . 4.4 mptp? . . . . . 0 C--O 1.251 1.161 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 176.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 63.6 t-105 . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.695 0.283 . . . . 0.0 111.309 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -61.1 156.36 49.56 Favored Pre-proline 0 N--CA 1.477 0.905 0 O-C-N 121.876 -0.515 . . . . 0.0 111.267 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.54 27.76 0.49 Allowed 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 121.803 1.669 . . . . 0.0 114.35 -173.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -109.56 2.93 20.69 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.606 -0.684 . . . . 0.0 112.042 168.652 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -150.55 -83.04 0.1 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -69.47 -45.85 68.05 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.416 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.64 -11.0 64.86 Favored Glycine 0 CA--C 1.542 1.755 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.061 178.596 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.98 -62.79 3.22 Favored Glycine 0 N--CA 1.469 0.884 0 C-N-CA 120.022 -1.085 . . . . 0.0 111.404 177.685 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.6 tp -85.92 -45.58 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.387 -174.654 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.6 mptp? . . . . . 0 C--O 1.25 1.105 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 172.219 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 13.3 t-105 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -156.53 172.86 5.55 Favored Pre-proline 0 CA--C 1.565 1.556 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -64.13 -28.33 65.11 Favored 'Trans proline' 0 CA--C 1.554 1.518 0 N-CA-C 115.757 1.407 . . . . 0.0 115.757 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.86 19.15 4.24 Favored 'General case' 0 CA--C 1.562 1.407 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 171.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -140.63 -78.59 0.29 Allowed 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -78.03 -44.67 25.82 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.682 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.04 -25.65 68.27 Favored Glycine 0 CA--C 1.552 2.357 0 C-N-CA 120.472 -0.87 . . . . 0.0 114.952 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.32 2.49 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.484 174.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.0 tp -88.13 -46.04 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 120.296 -0.562 . . . . 0.0 112.385 -169.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 118.462 -0.78 . . . . 0.0 110.065 -171.716 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 38.1 t-105 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -49.88 159.42 0.75 Allowed Pre-proline 0 N--CA 1.481 1.076 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -63.33 -11.94 28.02 Favored 'Trans proline' 0 CA--C 1.543 0.946 0 C-N-CA 122.575 2.184 . . . . 0.0 117.085 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 36.67 1.65 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 118.642 0.656 . . . . 0.0 111.377 168.629 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -154.62 -92.42 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -66.66 -48.94 67.79 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.87 -12.31 53.56 Favored Glycine 0 CA--C 1.541 1.715 0 N-CA-C 116.414 1.326 . . . . 0.0 116.414 177.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.46 -65.04 1.71 Allowed Glycine 0 N--CA 1.47 0.931 0 CA-C-N 118.611 1.206 . . . . 0.0 112.429 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.3 tp -92.79 -55.03 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.704 -0.748 . . . . 0.0 112.154 -174.003 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? . . . . . 0 C--O 1.27 2.133 0 CA-C-N 119.493 1.042 . . . . 0.0 108.72 178.756 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 . . . . . 0 N--CA 1.475 0.79 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -155.48 163.42 24.7 Favored Pre-proline 0 CA--C 1.56 1.335 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -55.65 -36.92 95.65 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.115 1.876 . . . . 0.0 116.598 -177.171 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.7 44.63 1.08 Allowed 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 172.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -154.77 -73.32 0.12 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 175.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 25.5 t80 -78.62 -44.25 24.37 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 121.987 -0.446 . . . . 0.0 111.809 174.371 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.95 -36.95 91.83 Favored Glycine 0 CA--C 1.545 1.967 0 N-CA-C 115.511 0.964 . . . . 0.0 115.511 178.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -75.46 -78.26 0.66 Allowed Glycine 0 CA--C 1.536 1.357 0 CA-C-N 117.921 0.861 . . . . 0.0 112.729 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.7 tp -78.83 -39.06 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -171.139 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt . . . . . 0 C--O 1.251 1.136 0 CA-C-N 119.162 0.892 . . . . 0.0 110.165 -174.387 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 25.5 t-105 . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.436 ' HB2' ' HD2' ' A' ' 3' ' ' PRO . 10.4 p30 -66.13 166.8 14.5 Favored Pre-proline 0 CA--C 1.55 0.958 0 O-C-N 121.803 -0.561 . . . . 0.0 112.077 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 2' ' ' ASN . 28.7 Cg_endo -73.5 15.89 0.51 Allowed 'Trans proline' 0 CA--C 1.543 0.938 0 N-CA-C 116.386 1.648 . . . . 0.0 116.386 -171.502 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -33.95 61.99 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 121.268 -0.895 . . . . 0.0 112.21 164.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -127.14 -62.86 1.08 Allowed 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.879 -0.513 . . . . 0.0 112.377 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -88.46 -48.46 7.59 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.272 -0.893 . . . . 0.0 112.314 -172.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.48 -48.28 82.09 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 115.469 0.948 . . . . 0.0 115.469 -168.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.34 -40.57 96.17 Favored Glycine 0 CA--C 1.536 1.361 0 C-N-CA 120.462 -0.875 . . . . 0.0 114.911 -175.518 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.435 HG23 ' H ' ' A' ' 10' ' ' LYS . 8.0 tp -93.06 -65.91 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 117.704 0.752 . . . . 0.0 110.804 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LYS . . . . . 0.435 ' H ' HG23 ' A' ' 9' ' ' ILE . 4.4 mptp? . . . . . 0 C--O 1.251 1.161 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 176.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 63.6 t-105 . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.695 0.283 . . . . 0.0 111.309 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -61.1 156.36 49.56 Favored Pre-proline 0 N--CA 1.477 0.905 0 O-C-N 121.876 -0.515 . . . . 0.0 111.267 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.54 27.76 0.49 Allowed 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 121.803 1.669 . . . . 0.0 114.35 -173.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -109.56 2.93 20.69 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.606 -0.684 . . . . 0.0 112.042 168.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -150.55 -83.04 0.1 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -69.47 -45.85 68.05 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.416 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.64 -11.0 64.86 Favored Glycine 0 CA--C 1.542 1.755 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.061 178.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.98 -62.79 3.22 Favored Glycine 0 N--CA 1.469 0.884 0 C-N-CA 120.022 -1.085 . . . . 0.0 111.404 177.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.6 tp -85.92 -45.58 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.387 -174.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.6 mptp? . . . . . 0 C--O 1.25 1.105 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 172.219 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 13.3 t-105 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -156.53 172.86 5.55 Favored Pre-proline 0 CA--C 1.565 1.556 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -64.13 -28.33 65.11 Favored 'Trans proline' 0 CA--C 1.554 1.518 0 N-CA-C 115.757 1.407 . . . . 0.0 115.757 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.86 19.15 4.24 Favored 'General case' 0 CA--C 1.562 1.407 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 171.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -140.63 -78.59 0.29 Allowed 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -78.03 -44.67 25.82 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.682 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.04 -25.65 68.27 Favored Glycine 0 CA--C 1.552 2.357 0 C-N-CA 120.472 -0.87 . . . . 0.0 114.952 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.32 2.49 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.484 174.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.0 tp -88.13 -46.04 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 120.296 -0.562 . . . . 0.0 112.385 -169.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 118.462 -0.78 . . . . 0.0 110.065 -171.716 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 38.1 t-105 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -49.88 159.42 0.75 Allowed Pre-proline 0 N--CA 1.481 1.076 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -63.33 -11.94 28.02 Favored 'Trans proline' 0 CA--C 1.543 0.946 0 C-N-CA 122.575 2.184 . . . . 0.0 117.085 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 36.67 1.65 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 118.642 0.656 . . . . 0.0 111.377 168.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -154.62 -92.42 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -66.66 -48.94 67.79 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.87 -12.31 53.56 Favored Glycine 0 CA--C 1.541 1.715 0 N-CA-C 116.414 1.326 . . . . 0.0 116.414 177.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.46 -65.04 1.71 Allowed Glycine 0 N--CA 1.47 0.931 0 CA-C-N 118.611 1.206 . . . . 0.0 112.429 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.3 tp -92.79 -55.03 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.704 -0.748 . . . . 0.0 112.154 -174.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? . . . . . 0 C--O 1.27 2.133 0 CA-C-N 119.493 1.042 . . . . 0.0 108.72 178.756 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 . . . . . 0 N--CA 1.475 0.79 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -155.48 163.42 24.7 Favored Pre-proline 0 CA--C 1.56 1.335 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -55.65 -36.92 95.65 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.115 1.876 . . . . 0.0 116.598 -177.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.7 44.63 1.08 Allowed 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 172.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -154.77 -73.32 0.12 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 175.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 25.5 t80 -78.62 -44.25 24.37 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 121.987 -0.446 . . . . 0.0 111.809 174.371 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.95 -36.95 91.83 Favored Glycine 0 CA--C 1.545 1.967 0 N-CA-C 115.511 0.964 . . . . 0.0 115.511 178.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -75.46 -78.26 0.66 Allowed Glycine 0 CA--C 1.536 1.357 0 CA-C-N 117.921 0.861 . . . . 0.0 112.729 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.7 tp -78.83 -39.06 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -171.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt . . . . . 0 C--O 1.251 1.136 0 CA-C-N 119.162 0.892 . . . . 0.0 110.165 -174.387 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 25.5 t-105 . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . 0.436 ' HB2' ' HD2' ' A' ' 3' ' ' PRO . 10.4 p30 -66.13 166.8 14.5 Favored Pre-proline 0 CA--C 1.55 0.958 0 O-C-N 121.803 -0.561 . . . . 0.0 112.077 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 2' ' ' ASN . 28.7 Cg_endo -73.5 15.89 0.51 Allowed 'Trans proline' 0 CA--C 1.543 0.938 0 N-CA-C 116.386 1.648 . . . . 0.0 116.386 -171.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -33.95 61.99 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 121.268 -0.895 . . . . 0.0 112.21 164.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -127.14 -62.86 1.08 Allowed 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.879 -0.513 . . . . 0.0 112.377 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -88.46 -48.46 7.59 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.272 -0.893 . . . . 0.0 112.314 -172.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.48 -48.28 82.09 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 115.469 0.948 . . . . 0.0 115.469 -168.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.34 -40.57 96.17 Favored Glycine 0 CA--C 1.536 1.361 0 C-N-CA 120.462 -0.875 . . . . 0.0 114.911 -175.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.435 HG23 ' H ' ' A' ' 10' ' ' LYS . 8.0 tp -93.06 -65.91 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 117.704 0.752 . . . . 0.0 110.804 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . 0.435 ' H ' HG23 ' A' ' 9' ' ' ILE . 4.4 mptp? . . . . . 0 C--O 1.251 1.161 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 176.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 63.6 t-105 . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.695 0.283 . . . . 0.0 111.309 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -61.1 156.36 49.56 Favored Pre-proline 0 N--CA 1.477 0.905 0 O-C-N 121.876 -0.515 . . . . 0.0 111.267 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.54 27.76 0.49 Allowed 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 121.803 1.669 . . . . 0.0 114.35 -173.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -109.56 2.93 20.69 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.606 -0.684 . . . . 0.0 112.042 168.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -150.55 -83.04 0.1 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -69.47 -45.85 68.05 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.416 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.64 -11.0 64.86 Favored Glycine 0 CA--C 1.542 1.755 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.061 178.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.98 -62.79 3.22 Favored Glycine 0 N--CA 1.469 0.884 0 C-N-CA 120.022 -1.085 . . . . 0.0 111.404 177.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.6 tp -85.92 -45.58 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.387 -174.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.6 mptp? . . . . . 0 C--O 1.25 1.105 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 172.219 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 13.3 t-105 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -156.53 172.86 5.55 Favored Pre-proline 0 CA--C 1.565 1.556 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -64.13 -28.33 65.11 Favored 'Trans proline' 0 CA--C 1.554 1.518 0 N-CA-C 115.757 1.407 . . . . 0.0 115.757 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.86 19.15 4.24 Favored 'General case' 0 CA--C 1.562 1.407 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 171.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -140.63 -78.59 0.29 Allowed 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -78.03 -44.67 25.82 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.682 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.04 -25.65 68.27 Favored Glycine 0 CA--C 1.552 2.357 0 C-N-CA 120.472 -0.87 . . . . 0.0 114.952 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.32 2.49 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.484 174.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.0 tp -88.13 -46.04 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 120.296 -0.562 . . . . 0.0 112.385 -169.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 118.462 -0.78 . . . . 0.0 110.065 -171.716 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 38.1 t-105 . . . . . 0 N--CA 1.48 1.049 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.3 p30 -49.88 159.42 0.75 Allowed Pre-proline 0 N--CA 1.481 1.076 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 178.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -63.33 -11.94 28.02 Favored 'Trans proline' 0 CA--C 1.543 0.946 0 C-N-CA 122.575 2.184 . . . . 0.0 117.085 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -98.95 36.67 1.65 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 118.642 0.656 . . . . 0.0 111.377 168.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -154.62 -92.42 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -66.66 -48.94 67.79 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -64.87 -12.31 53.56 Favored Glycine 0 CA--C 1.541 1.715 0 N-CA-C 116.414 1.326 . . . . 0.0 116.414 177.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.46 -65.04 1.71 Allowed Glycine 0 N--CA 1.47 0.931 0 CA-C-N 118.611 1.206 . . . . 0.0 112.429 177.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.3 tp -92.79 -55.03 6.55 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 CA-C-N 114.704 -0.748 . . . . 0.0 112.154 -174.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? . . . . . 0 C--O 1.27 2.133 0 CA-C-N 119.493 1.042 . . . . 0.0 108.72 178.756 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 9.2 t-105 . . . . . 0 N--CA 1.475 0.79 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.8 p30 -155.48 163.42 24.7 Favored Pre-proline 0 CA--C 1.56 1.335 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 178.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -55.65 -36.92 95.65 Favored 'Trans proline' 0 CA--C 1.55 1.294 0 C-N-CA 122.115 1.876 . . . . 0.0 116.598 -177.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -95.7 44.63 1.08 Allowed 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 172.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -154.77 -73.32 0.12 Allowed 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 175.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 25.5 t80 -78.62 -44.25 24.37 Favored 'General case' 0 N--CA 1.48 1.029 0 O-C-N 121.987 -0.446 . . . . 0.0 111.809 174.371 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.95 -36.95 91.83 Favored Glycine 0 CA--C 1.545 1.967 0 N-CA-C 115.511 0.964 . . . . 0.0 115.511 178.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -75.46 -78.26 0.66 Allowed Glycine 0 CA--C 1.536 1.357 0 CA-C-N 117.921 0.861 . . . . 0.0 112.729 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.7 tp -78.83 -39.06 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.325 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -171.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt . . . . . 0 C--O 1.251 1.136 0 CA-C-N 119.162 0.892 . . . . 0.0 110.165 -174.387 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 25.5 t-105 . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.436 ' HB2' ' HD2' ' A' ' 3' ' ' PRO . 10.4 p30 -66.13 166.8 14.5 Favored Pre-proline 0 CA--C 1.55 0.958 0 O-C-N 121.803 -0.561 . . . . 0.0 112.077 -179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 2' ' ' ASN . 28.7 Cg_endo -73.5 15.89 0.51 Allowed 'Trans proline' 0 CA--C 1.543 0.938 0 N-CA-C 116.386 1.648 . . . . 0.0 116.386 -171.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -74.95 -33.95 61.99 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 121.268 -0.895 . . . . 0.0 112.21 164.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.2 p-10 -127.14 -62.86 1.08 Allowed 'General case' 0 N--CA 1.475 0.798 0 O-C-N 121.879 -0.513 . . . . 0.0 112.377 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 40.7 t80 -88.46 -48.46 7.59 Favored 'General case' 0 N--CA 1.477 0.884 0 O-C-N 121.272 -0.893 . . . . 0.0 112.314 -172.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -57.48 -48.28 82.09 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 115.469 0.948 . . . . 0.0 115.469 -168.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -59.34 -40.57 96.17 Favored Glycine 0 CA--C 1.536 1.361 0 C-N-CA 120.462 -0.875 . . . . 0.0 114.911 -175.518 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.435 HG23 ' H ' ' A' ' 10' ' ' LYS . 8.0 tp -93.06 -65.91 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 117.704 0.752 . . . . 0.0 110.804 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . 0.435 ' H ' HG23 ' A' ' 9' ' ' ILE . 4.4 mptp? . . . . . 0 C--O 1.251 1.161 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 176.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 63.6 t-105 . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.695 0.283 . . . . 0.0 111.309 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -61.1 156.36 49.56 Favored Pre-proline 0 N--CA 1.477 0.905 0 O-C-N 121.876 -0.515 . . . . 0.0 111.267 179.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -78.54 27.76 0.49 Allowed 'Trans proline' 0 CA--C 1.543 0.934 0 C-N-CA 121.803 1.669 . . . . 0.0 114.35 -173.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -109.56 2.93 20.69 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.606 -0.684 . . . . 0.0 112.042 168.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.2 t70 -150.55 -83.04 0.1 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 179.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -69.47 -45.85 68.05 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.416 -178.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.64 -11.0 64.86 Favored Glycine 0 CA--C 1.542 1.755 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.061 178.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.98 -62.79 3.22 Favored Glycine 0 N--CA 1.469 0.884 0 C-N-CA 120.022 -1.085 . . . . 0.0 111.404 177.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.6 tp -85.92 -45.58 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.822 0 C-N-CA 120.193 -0.603 . . . . 0.0 111.387 -174.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 5.6 mptp? . . . . . 0 C--O 1.25 1.105 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 172.219 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' TRP . . . . . . . . . . . . . 13.3 t-105 . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -156.53 172.86 5.55 Favored Pre-proline 0 CA--C 1.565 1.556 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -64.13 -28.33 65.11 Favored 'Trans proline' 0 CA--C 1.554 1.518 0 N-CA-C 115.757 1.407 . . . . 0.0 115.757 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -88.86 19.15 4.24 Favored 'General case' 0 CA--C 1.562 1.407 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 171.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -140.63 -78.59 0.29 Allowed 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -177.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' TYR . . . . . . . . . . . . . 43.4 t80 -78.03 -44.67 25.82 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.682 178.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -63.04 -25.65 68.27 Favored Glycine 0 CA--C 1.552 2.357 0 C-N-CA 120.472 -0.87 . . . . 0.0 114.952 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.32 2.49 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.484 174.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.0 tp -88.13 -46.04 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 C-N-CA 120.296 -0.562 . . . . 0.0 112.385 -169.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt . . . . . 0 N--CA 1.484 1.233 0 CA-C-O 118.462 -0.78 . . . . 0.0 110.065 -171.716 . . . . . . . . 0 0 . 1 stop_ save_